KD-414 explained

Type:	vaccine
Target:	SARS-CoV-2
Vaccine Type:	inactivated
Routes Of Administration:	Intramuscular

KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co.^{[1] [2]} Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.^[3]

Notes and References

1. News: Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate . Reuters . 22 March 2021.
2. Web site: 18歳以上の健康な日本人を対象に、COVID-19に対するワクチン（KD-414）を2回接種した際の免疫原性及び安全性を確認する多施設共同非盲検非対照試験。 . jrct.niph.go.jp . Japan Registry of Clinical Trials . 22 October 2021 .
3. Tanishima M, Ibaraki K, Kido K, Nakayama S, Ata K, Nakamura H, Shinmura Y, Sonoda K, Ueda K, Oda Y . 6 . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan . 29 June 2022 . 10.1101/2022.06.28.22276794.